Abiopharma

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Stran & Company Schedules 2025 Fiscal Year Financial Results and Business Update Conference Call

EZCORP to Host Annual Meeting of Stockholders on Thursday, March 26, 2026

Skyline Builders Group Holding Limited Announces Pricing of Private Placement of Convertible Notes and Preferred Shares

State Street to Support Dimensional Fund Advisors’ First-Ever ETF Share Class Rollout for U.S. Mutual Funds

Draganfly and Palladyne AI Achieve Integration Milestone Advancing Autonomous Swarm Capabilities

Rubico Announces Filing of 2025 Annual Report on Form 20-F

Eco Wave Power Advances Taiwan Expansion as Partner Signs Land Lease for Suao Port Wave Energy Project

Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus